Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Oral Hypoglyceimic Agents (OHAs) Market by Type (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), By Application (Hospitals and Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Oral Hypoglyceimic Agents (OHAs) Market by Type (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), By Application (Hospitals and Clinics, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 204729 3300 Pharma & Healthcare 377 245 Pages 4.6 (45)
                                          

The global oral hypoglycemics market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing prevalence of diabetes and obesity, which are major risk factors for type 2 diabetes mellitus (T2DM). The increasing number of people with T2DM has led to an increase in the demand for oral hypoglycemic agents. The global oral hypoglycemics market is segmented by type, application and region. On the basis of type, it can be classified into sulfonylureas, metformin, thiazolidinediones and alphglucosidase inhibitors. On the basis of application it can be classified into hospitals and clinics. On the basis of region it can be classified into North America, Latin America, Europe Asia Pacific and Middle East & Africa regions.

  1. The global Oral Hypoglycemics market is driven by factors such as increasing prevalence of diabetes and obesity, rising awareness about the benefits of OHAs, and growing demand for oral hypoglycemic agents in emerging economies such as China and India.
  2. Increasing prevalence of diabetes and obesity: Diabetes is a chronic disease that affects the way your body uses sugar (glucose). It can lead to serious health problems if not managed properly, including heart disease, stroke, blindness or kidney failure.
  3. Rising awareness about the benefits of OHAs: Awareness about the benefits of OHAs has increased due to various campaigns undertaken by pharmaceutical companies in order to educate people on how they can manage their blood sugar levels with these drugs.
  4. Growing demand for oral hypoglycemic agents in emerging economies: Emerging economies such as China and India are witnessing an increase in demand for oral hypoglycemic agents due to increasing incidence rates among diabetic patients.

Industry Growth Insights published a new data on “Oral Hypoglyceimic Agents (OHAs) Market”. The research report is titled “Oral Hypoglyceimic Agents (OHAs) Market research by Types (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), By Applications (Hospitals and Clinics, Others), By Players/Companies Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Oral Hypoglyceimic Agents (OHAs) Market Research Report

By Type

Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors

By Application

Hospitals and Clinics, Others

By Companies

Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

245

Number of Tables & Figures

172

Customization Available

Yes, the report can be customized as per your need.


Global Oral Hypoglyceimic Agents (OHAs) Industry Outlook


Global Oral Hypoglyceimic Agents (OHAs) Market Report Segments:

The global Oral Hypoglyceimic Agents (OHAs) market is segmented on the basis of:

Types

Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals and Clinics, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Pfizer
  2. GlaxoSmithKline
  3. Bayer
  4. Bristol-Myers Squibb
  5. Novonordisk
  6. Sanofi-Aventis
  7. Servier
  8. Huadong Medicine
  9. Wanbang Biopharmaceuticals
  10. Double-Crane Pharmaceutical
  11. Guangzhou Pharmaceutical

Global Oral Hypoglyceimic Agents (OHAs) Market Overview


Highlights of The Oral Hypoglyceimic Agents (OHAs) Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Sulfonylureas
    2. Metformin
    3. Thiazolidinediones
    4. Alpha-Glucosidase Inhibitors
  1. By Application:

    1. Hospitals and Clinics
    2. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Oral Hypoglyceimic Agents (OHAs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Oral Hypoglyceimic Agents (OHAs) Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Oral hypoglyceimics are medications that help to lower blood sugar levels. They are often used in combination with other treatments, such as insulin, to manage diabetes.

Some of the major players in the oral hypoglyceimic agents (ohas) market are Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical.

The oral hypoglyceimic agents (ohas) market is expected to register a CAGR of 4.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Oral Hypoglyceimic Agents (OHAs) Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Oral Hypoglyceimic Agents (OHAs) Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Oral Hypoglyceimic Agents (OHAs) Market - Supply Chain
   4.5. Global Oral Hypoglyceimic Agents (OHAs) Market Forecast
      4.5.1. Oral Hypoglyceimic Agents (OHAs) Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Oral Hypoglyceimic Agents (OHAs) Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Oral Hypoglyceimic Agents (OHAs) Market Absolute $ Opportunity

5. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      5.3.1. Sulfonylureas
      5.3.2. Metformin
      5.3.3. Thiazolidinediones
      5.3.4. Alpha-Glucosidase Inhibitors
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      6.3.1. Hospitals and Clinics
      6.3.2. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026

9. North America Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      9.4.1. Hospitals and Clinics
      9.4.2. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      9.7.1. Sulfonylureas
      9.7.2. Metformin
      9.7.3. Thiazolidinediones
      9.7.4. Alpha-Glucosidase Inhibitors
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026

10. Latin America Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      10.4.1. Hospitals and Clinics
      10.4.2. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      10.7.1. Sulfonylureas
      10.7.2. Metformin
      10.7.3. Thiazolidinediones
      10.7.4. Alpha-Glucosidase Inhibitors
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026

11. Europe Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      11.4.1. Hospitals and Clinics
      11.4.2. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      11.7.1. Sulfonylureas
      11.7.2. Metformin
      11.7.3. Thiazolidinediones
      11.7.4. Alpha-Glucsidase Inhibitors
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026

12. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      12.4.1. Hospitals and Clinics
      12.4.2. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      12.7.1. Sulfonylureas
      12.7.2. Metformin
      12.7.3. Thiazolidinediones
      12.7.4. Alpha-Glucosidase Inhibitors
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026

13. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
      13.4.1. Hospitals and Clinics
      13.4.2. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
      13.7.1. Sulfonylureas
      13.7.2. Metformin
      13.7.3. Thiazolidinediones
      13.7.4. Alpha-Glucosidase Inhibitors
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Oral Hypoglyceimic Agents (OHAs) Market: Market Share Analysis
   14.2. Oral Hypoglyceimic Agents (OHAs) Distributors and Customers
   14.3. Oral Hypoglyceimic Agents (OHAs) Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Pfizer
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. GlaxoSmithKline
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Bayer
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Bristol-Myers Squibb
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Novonordisk
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Sanofi-Aventis
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Servier
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Huadong Medicine
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Wanbang Biopharmaceuticals
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Double-Crane Pharmaceutical
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Guangzhou Pharmaceutical
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us